3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Completed
2
Unknown
1
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
6
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Triple Negative Breast Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
20
Carboplatin
14
Cyclophosphamide
12
atezolizumab
11
Paclitaxel
10
Albumin-Bound Paclitaxel
8
Capecitabine
7
Nivolumab
6
130-nm albumin-bound paclitaxel
6
spartalizumab
5
fludarabine
5
Taxes
5
Gemcitabine
5
talazoparib
4
bintrafusp alfa protein, human
4
avelumab
4
Cisplatin
4
sacituzumab govitecan
3
olaparib
3
entinostat
3
Leucovorin
3
Ipilimumab
3
Immunoglobulin G
3
Drug Therapy
3
Doxorubicin
3
Docetaxel
3
Biopsy
3
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
3
trilaciclib
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Triple Negative Breast Neoplasms
×
Mastectomy, Segmental
×
Clear all
NCT01234532
2022-05-03
0927GCC
University of Maryland, Baltimore
Phase 2
Terminated
5 enrolled
7 charts